Почетна › Difuzni veliki B-ćelijski limfom › Mičigen
Kliničke studije za Difuzni veliki B-ćelijski limfom u državi Mičigen
17 studija za Difuzni veliki B-ćelijski limfom traži učesnike na lokacijama u državi Mičigen.
Gradovi u državi Mičigen
Zvanični tekst studije (na engleskom)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545), Ann Arbor
- Karmanos Cancer Institute ( Site 0174), Detroit
- Corewell Health ( Site 0130), Grand Rapids
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06717347Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Corewell Health, Grand Rapids
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06806033Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- OSF Saint Francis Hospital and Medical Group, Escanaba
- Schoolcraft Memorial Hospital, Manistique
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06649812Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Karmanos Cancer Center (Wayne State University), Detroit
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT05852717A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Henry Ford Health System, Detroit
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07101328A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Corewell Health ( Site 0162), Grand Rapids
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05139017Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Research Site, Detroit
Тражи се учесникФаза 2
Узраст од 65 до 99 · Оба пола · Ажурирано 30. 10. 2026. · NCT05952024Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
Тражи се учесникФаза 1/2
6 Months – 25 Years · Оба пола · Ажурирано 30. 10. 2026. · NCT06395103Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- и још 12
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05890352Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
- University of Michigan Rogel Cancer Center, Ann Arbor
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07892027A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Midwest, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT07424833Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Bronson Battle Creek, Battle Creek
- Henry Ford Macomb Hospital-Clinton Township, Clinton Township
- Henry Ford Medical Center-Fairlane, Dearborn
- и још 15
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT05633615A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- University of Michigan, Ann Arbor
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07195916A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Karmanos Cancer Institute, Detroit
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Corewell Health, Grand Rapids
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT05826535DALY II USA/ MB-CART2019.1 for DLBCL
- University of Michigan, Ann Arbor
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT04792489Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.